Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Julianne PeabodyDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Susan B CoreDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Larance RonsardThe Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Daniel LingwoodThe Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
David S PeabodyDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Bryce ChackerianDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. BChackerian@salud.unm.edu.
Funding
Unfolded Protein Response and Autophagy in T Helper Cell Effector FunctionP20GM121176 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Monica Rosas Lemus · 2017 to 2026
$24.9M
The Gonorrhea Vaccine Cooperative Research CenterU19AI144180 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MACINTYRE, ANDREW · 2019 to 2023
$10.7M
Biology of Infectious Diseases &InflammationT32AI007538 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Michelle A Ozbun · 1998 to 2026
$5.2M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Opioid vaccine development using bacteriophage virus-like particle (VLP) immunogensR01HL131696 · NHLBI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CHACKERIAN, BRYCE C · 2017 to 2020
$2.0M
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoireR01AI124378 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2017 to 2020
$2.0M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
Antibody complementarity determining regions (CDRs) participate in antigen recognition, but not all participate equally in antigen binding. Here we describe a technique for discovering strong, specific binding partners to defined motifs within the CDRs of chimeric, engineered antibodies using affinity selection and counter-selection of epitopes displayed on bacteriophage MS2-based virus-like particles (VLPs). As an example, we show how this technique can be used to identify families of VLPs that interact with antibodies displaying the CDRs encoded by the germline precursor of a broadly neutralizing monoclonal antibody against HIV-1.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
An Approach for Antigen-Agnostic Identification of Virus-Like Particle-Displayed Epitopes that Engage Specific Antibody V Gene Regions. · full record | Socratic